GBT Bucks Gene Therapy Trend With Sanofi Sickle Cell Deal
Pact Could Be Worth $353m
Executive Summary
Building on Oxbryta, which is already approved in the US for the rare blood disorder, Global Blood Therapeutics has licensed two sickle cell disease programs from Sanofi.
You may also be interested in...
Top 5 Deals Of 2022: The Economic Drag On M&A Continues
Many of the same factors that held down large M&A transactions in 2021 carried over to 2022, which saw eight buyouts valued at $2bn+, headlined by Amgen’s $27.8bn purchase of Horizon.
Pfizer’s Buying Spree Continues With GBT, Gaining A Sickle Cell Disease Franchise
Pfizer has reached a deal to buy Global Blood Therapeutics for $5.4bn, gaining the sickle cell therapy Oxbryta and building on efforts to reach underserved patient groups.
Bluebird Bio Gets Relief, But Gene Therapy Hurdles Remain
The jury is still out on the case of MDS and some remaining questions regarding the AML case may still hinder commercial uptake.